Compass Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$176.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Compass Therapeutics's estimated annual revenue is currently $6M per year.(i)
  • Compass Therapeutics received $132.0M in venture funding in July 2018.
  • Compass Therapeutics's estimated revenue per employee is $155,000
  • Compass Therapeutics's total funding is $176.5M.

Employee Data

  • Compass Therapeutics has 39 Employees.(i)
  • Compass Therapeutics grew their employee count by -20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Were building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures. To learn more, visit www.compasstherapeutics.com

keywords:N/A

$176.5M

Total Funding

39

Number of Employees

$6M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Compass Therapeutics News

2022-03-30 - Compass Therapeutics Announces Presentation on CTX ...

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology...

2022-03-22 - Compass Therapeutics Reports Fourth Quarter and Full Year ...

BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...

2021-03-05 - Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Mar 5, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today reported fourth quarter and ...

2021-03-04 - Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”

BOSTON--(BUSINESS WIRE)--Mar 4, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, announced today that shares of the ...

2018-07-12 - Compass Therapeutics Completes $132M Series A Financing

Compass Therapeutics, a Cambridge, MA-based biotechnology company committed to comprehensively drugging the human immune system, closed the final $49m tranche of its $132m Series A financing. The round was led by OrbiMed Advisors and included F-Prime Capital, Cowen Healthcare Investments, Thiel ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9M390%N/A
#2
$6.4M39-2%N/A
#3
$6M3970%$28.4M
#4
$5.6M3956%N/A
#5
N/A3950%$16.4M

Compass Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-07-12$132.0MAOrbiMed AdvisorsArticle